AI Pipeline Can Accurately Measure Sarcopenia in Head and Neck Cancer
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 14, 2023 -- A fully automated deep learning pipeline can accurately measure sarcopenia in head and neck squamous cell carcinoma (HNSCC), which is associated with disease outcomes, according to a study published online Aug. 10 in JAMA Network Open.
Zezhong Ye, Ph.D., from Harvard Medical School in Boston, and colleagues developed and externally validated a fully automated image-based deep learning platform for cervical vertebral muscle segmentation and skeletal muscle index (SMI) calculation. Associations with survival and treatment toxicity outcomes were examined using data for 899 patients with HNSCC undergoing primary radiation with abdominal computed tomography scans and complete clinical information.
The researchers found that the dice similarity coefficients for the validation set and internal test set (96 and 48 participants, respectively) were both 0.90, with a mean 96.2 percent acceptable rate between two reviewers on external clinical testing (377 participants). Across datasets, estimated cross-sectional area and SMI values were associated with manually annotated values. Compared with no sarcopenia, SMI-derived sarcopenia was associated with worse overall survival and longer feeding tube duration (162 versus 134 days).
"If further validated, our end-to-end deep learning pipeline could be incorporated into standard clinical practice for directing future treatment approaches and clinical decision making, as well as for individualized supportive measures, including nutrition guidance and physical therapy," the authors write.
Several authors disclosed ties to the pharmaceutical and biopharmaceutical industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
American Association for Cancer Research, April 5-10
The annual meeting of the American Association for Cancer Research was held this year from April 5 to 10 in San Diego, drawing approximately 19,000 participants from around the...
AACR: Novel Personalized Vaccine Feasible for Head and Neck Cancer
TUESDAY, April 9, 2024 -- The novel viral-based personalized cancer vaccine, TG4050, which encodes up to 30 patient- and tumor-specific sequences is feasible and safe for patients...
Decrease in Head and Neck Cancer Incidence Seen During Pandemic
FRIDAY, Jan. 12, 2024 -- During the first year of the COVID-19 pandemic, the incidence of head and neck cancer (HNC) decreased, according to a study published online Jan. 11 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.